1/18/2023 8:09:04 AM
NeuroBo Pharma Appoints Joseph Hooker As Interim CEO And President
9/15/2022 8:38:06 AM
NeuroBo Collaborates To License And Develop Portfolio Of Dong-A's Cardio-Metabolic Therapies; Stock Surges
9/12/2022 9:20:38 AM
NeuroBo Pharmaceuticals Announces 1-for-30 Reverse Split Of Common Stock
5/6/2022 8:10:22 AM
NeuroBo Pharma Appoints Matthew Bardin As SVP Operations
4/1/2022 8:06:53 AM
NeuroBo Pharma FY Net Loss $15.3 Mln Or $0.66/shr Vs Net Loss Of $29.7 Mln, Or $1.83/shr Last Year
11/15/2021 8:09:44 AM
NeuroBo Pharmaceuticals Q3 Net Loss $3.5 Mln Or $0.16/shr Vs. Net Loss $3.1 Mln Or $0.19/shr Last Year